SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-24-023384
Filing Date
2024-03-18
Accepted
2024-03-18 13:45:06
Documents
2
Group Members
CLS THERAPEUTICS LTD.DMITRY GENKINGEORGY TETSM. SCOTT MAGUIREVICTOR TETS

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D ea0202011-13da2cls_xenetic.htm SC 13D/A 93032
2 JOINT FILING AGREEMENT, DATED JUNE 14, 2023 ea020201101ex99-1_xenetic.htm EX-99.1 9753
  Complete submission text file 0001213900-24-023384.txt   104646
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Subject) CIK: 0001534525 (see all company filings)

IRS No.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89709 | Film No.: 24758180
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 646-617-3088
CLS Therapeutics, LLC (Filed by) CIK: 0001951493 (see all company filings)

IRS No.: 920236145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A